AVAILABLE MEDICINE FOR Nintedanib
There are no products to list.
Introduction to Nintedanib
Nintedanib is an oral drug that has been approved mainly for the treatment of idiopathic pulmonary fibrosis and some forms of lung cancer. It acts through the inhibition of tyrosine kinase, which consequently blocks several signaling pathways implicated in the development of fibrosis and tumor growth. It offers inhibition of VEGF receptors, FGF receptors, and PDGF receptors, and was shown, in this way, to reduce the progression of fibrosis and the risk of decline in lung function in IPF patients. In lung cancer treatment, this drug can be used in combination with chemotherapy for selected tumor types. Common adverse effects associated with the use of nintedanib include diarrhea, nausea, and liver function abnormality.
This treatment also requires regular monitoring of liver enzymes. The patients should be counseled on hydration and dietary changes that can best help mitigate the gastrointestinal side effects. The oral form of Nintedanib is usually administered in capsule form, taken twice a day with food. It is important to ensure that the patient complies with the prescription and returns for follow-up as scheduled to regularly review the effectiveness of the drug and look out for signs and symptoms of possible adverse events.
